- Home
- PTA vs CLDX Comparison
PTA vs CLDX Comparison
Compare PTA & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- CLDX
- Stock Information
- Founded
- PTA 2020
- CLDX N/A
- Country
- PTA United States
- CLDX United States
- Employees
- PTA N/A
- CLDX N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PTA Finance
- CLDX Health Care
- Exchange
- PTA Nasdaq
- CLDX Nasdaq
- Market Cap
- PTA 1.1B
- CLDX 1.3B
- IPO Year
- PTA N/A
- CLDX 2008
- Fundamental
- Price
- PTA $19.97
- CLDX $22.81
- Analyst Decision
- PTA
- CLDX Buy
- Analyst Count
- PTA 0
- CLDX 9
- Target Price
- PTA N/A
- CLDX $50.00
- AVG Volume (30 Days)
- PTA 159.2K
- CLDX 865.2K
- Earning Date
- PTA 01-01-0001
- CLDX 08-11-2025
- Dividend Yield
- PTA 8.31%
- CLDX N/A
- EPS Growth
- PTA N/A
- CLDX N/A
- EPS
- PTA N/A
- CLDX N/A
- Revenue
- PTA N/A
- CLDX $7,559,000.00
- Revenue This Year
- PTA N/A
- CLDX N/A
- Revenue Next Year
- PTA N/A
- CLDX N/A
- P/E Ratio
- PTA N/A
- CLDX N/A
- Revenue Growth
- PTA N/A
- CLDX 24.49
- 52 Week Low
- PTA $15.84
- CLDX $14.40
- 52 Week High
- PTA $19.67
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- PTA 56.22
- CLDX 54.64
- Support Level
- PTA $19.75
- CLDX $21.57
- Resistance Level
- PTA $20.01
- CLDX $24.06
- Average True Range (ATR)
- PTA 0.18
- CLDX 1.11
- MACD
- PTA -0.01
- CLDX -0.11
- Stochastic Oscillator
- PTA 73.47
- CLDX 49.80
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.